Actively Recruiting

Phase Not Applicable
Age: 0 - 25Years
All Genders
NCT03810196

CD45RA Depleted Peripheral Stem Cell Addback for Viral or Fungal Infections Post TCRαβ/CD19 Depleted HSCT

Led by Children's Hospital of Philadelphia · Updated on 2026-02-20

50

Participants Needed

1

Research Sites

465 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The major morbidities of allogeneic hematopoietic stem cell transplant with non-human leukocyte antigen (HLA) matched siblings are graft vs host disease (GVHD) and life threatening infections. T depletion of the donor hematopoietic stem cell graft is effective in preventing GVHD, but immune reconstitution is slow, increasing the risk of infections. An addback of donor CD45RA (naive T cells) depleted cells may improve immune reconstitution and help decrease the risk of infections.

CONDITIONS

Official Title

CD45RA Depleted Peripheral Stem Cell Addback for Viral or Fungal Infections Post TCRαβ/CD19 Depleted HSCT

Who Can Participate

Age: 0 - 25Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Patients younger than 25 years.
  • First allogeneic hematopoietic stem cell transplant only.
  • Diagnosis of acute leukemias at high risk for relapse or related hematologic malignancies including acute myeloid leukemia, myelodysplastic syndromes, acute lymphoblastic leukemia, mixed lineage or bi-phenotypic leukemia, lymphoblastic lymphoma, Burkitt lymphoma, or juvenile myelomonocytic leukemia.
  • Evaluation of organ and infectious status according to bone marrow transplant standard procedures.
  • Signed consent by parent/guardian or patient if older than 18 years.
Not Eligible

You will not qualify if you...

  • Patients who do not meet institutional disease, organ, or infection criteria.
  • No suitable donor available for mobilized peripheral stem cells.
  • Patients with genetic disorders such as Fanconi anemia, Kostmann syndrome, dyskeratosis congenita, or other DNA repair defects.
  • Patients with Hodgkin lymphoma or lymphoma types other than Burkitt or lymphoblastic lymphoma.
  • Pregnant participants.

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Children's Hospital of Philadelphia

Philadelphia, Pennsylvania, United States, 19104

Actively Recruiting

Loading map...

Research Team

M

Megan Atkinson

CONTACT

P

Patricia Hankins, BSN, RN, CCRC

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NON_RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here